The reaction leaves a 3'-hydroxy group is left at the tRNA end, and a 5'-phosphoryl group at the cleaved, trailing end. The reaction requires
zinc ions as
co-factors.
^Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9.
PMID11522646.
^
abRökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41.
PMID11507049.
Rökman A, Ikonen T, Mononen N, et al. (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41.
PMID11507049.
Wang L, McDonnell SK, Elkins DA, et al. (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9.
PMID11522646.
Stanford JL, Sabacan LP, Noonan EA, et al. (2003). "Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study". Cancer Epidemiol. Biomarkers Prev. 12 (9): 876–81.
PMID14504198.
The reaction leaves a 3'-hydroxy group is left at the tRNA end, and a 5'-phosphoryl group at the cleaved, trailing end. The reaction requires
zinc ions as
co-factors.
^Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9.
PMID11522646.
^
abRökman A, Ikonen T, Mononen N, Autio V, Matikainen MP, Koivisto PA, Tammela TL, Kallioniemi OP, Schleutker J (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41.
PMID11507049.
Rökman A, Ikonen T, Mononen N, et al. (2001). "ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer". Cancer Res. 61 (16): 6038–41.
PMID11507049.
Wang L, McDonnell SK, Elkins DA, et al. (2001). "Role of HPC2/ELAC2 in hereditary prostate cancer". Cancer Res. 61 (17): 6494–9.
PMID11522646.
Stanford JL, Sabacan LP, Noonan EA, et al. (2003). "Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study". Cancer Epidemiol. Biomarkers Prev. 12 (9): 876–81.
PMID14504198.